Join
Live feed
·
PRReleasevia Quantisnow
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

ByQuantisnow·Wall Street's wire, on your screen.
XENE· Xenon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XENE (Xenon Pharmaceuticals Inc.) and more on Quantisnow.